Burkitt's lymphoma is a rare and aggressive blood cancer characterized by a translocation of the MYC gene. It occurs most ...

The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal ...

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) ...

In this MedPage Today video, Taylor Brooks, MD, of the Cleveland Clinic Cancer Institute, discusses real-world survival ...

Based on phase 3 trial data, the FDA accepted an sBLA for nivolumab plus AVD for untreated stage III or IV classical Hodgkin lymphoma.

BEIJING -- China's pediatric and adolescent cancer patients have achieved a 5-year survival rate of 77.2 percent, marking significant progress, with some specific types reaching world-class levels, ...

Some cancers may not require immediate treatment, from prostate cancer to thyroid tumors. Medical experts share when ...

Allie Reece has shared her cancer journey on TikTok, where she has built a supportive community of thousands of followers ...

The 30th European Hematology Association (EHA) Congress (EHA 2025), held in Milan, Italy, from June 12-15, 2025, continued ...

BEIJING, Dec. 24 (Xinhua) -- China's pediatric and adolescent cancer patients have achieved a 5-year survival rate of 77.2 percent, marking significant progress, with some specific types reaching ...

Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...